Management of Ewing sarcoma family of tumors: Current scenario and unmet need

Table 3 Selected studies of high dose chemotherapy with stem cell rescue in Ewing sarcoma family tumors

Study (type)	Disease setting	n	Conditioning	Conclusion
CESS (restrospective)[78]	Recurrent or progressive disease (HDC after CR or PR)	73	BuMel (15) TreoMel (38) Other (20)	Early relapse - poor prognostic
Société Française des Cancers de l’Enfant (prospective)[8]	Metastatic at diagnosis	75	BuMel	Beneficial for lung only or bone metastases
Italian Sarcoma Group/Scandinavian Sarcoma Group IV Protocol (phase II)[9]	Metastatic at diagnosis (lung or single bone metastasis)	79	BuMel ± TBI	HDC with WLI is effective
Italian Sarcoma Group/Scandinavian Sarcoma Group III Protocol (prospective)[34]	High risk, localized	126	BuMel	Effective and feasible in patients with PR after chemotherapy
Euro-Ewing 99 (prospective)[10]	Metastatic at diagnosis	169	BuMel (123) Mel (15) Others (20)	Effective in Bone and Bone marrow metastases
EBMT registry (retrospective)[79]	Metastatic and HR, localized (n = 2411) Recurrent (n = 719)	3695	Heterogeneous regimens	Prognostic factors: Age, response to treatment, BuMel regimen

BuMel: Busulphan and melphalan; CR: Complete response; ESFT: Ewing sarcoma family of tumors; HDC: High dose chemotherapy; HR: High risk; n: Number; PR: Partial response; TBI: Total body irradiation; TreoMel: Treosulphan and melphalan; WLI: Whole lung irradiation.